Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk PopulationPaul G. Richardson, Joan Bladé, Xavier Leleu et al.|Clinical Lymphoma Myeloma & Leukemia|2019Cited by 3
S1605 HORIZON (OP‐106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM)Paul G. Richardson, M.‐V. Mateos, Albert Oriol et al.|HemaSphere|2019Cited by 2
HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and SafetyPaul G. Richardson, María‐Victoria Mateos, Albert Oriol et al.|Clinical Lymphoma Myeloma & Leukemia|2019Cited by 2
MM-133: HORIZON (OP-106): Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody (mAb) – Final Primary AnalysisPaul G. Richardson, María‐Victoria Mateos, Albert Oriol et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 0